CureVac N.V. (CVAC): $5.57
Market Cap: $1.25 B
Deal Value: $1.25 B
German biotech firm BioNTech SE (BNTX) entered a merger agreement on June 12, 2025, to acquire domestic peer CureVac in a deal valued at $1.25 billion.
Under the terms of the agreement, each CureVac share will be exchanged for about $5.46 in BioNTech American Depositary Receipts (ADSs), representing a premium of 34.15% from the stock’s last close.